within Pharmacolibrary.Drugs.ATC.L;

model L02BG04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.99,
    Cl             = 6.166666666666667e-07,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0018700000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004350000000000001,
    Tlag           = 12.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L02BG04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Letrozole is a non-steroidal aromatase inhibitor used primarily in the treatment of hormonally-responsive breast cancer after surgery. It works by decreasing estrogen production, which is linked to the growth of breast tumors. Letrozole is approved and widely used today as an adjuvant treatment in postmenopausal women.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy postmenopausal women after single oral dose.</p><h4>References</h4><ol><li><p>Cortés, J, et al., &amp; Bardia, A (2024). Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5. <i>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</i> 42(22) 2680–2690. DOI:<a href=\"https://doi.org/10.1200/JCO.23.02036\">10.1200/JCO.23.02036</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38889373/\">https://pubmed.ncbi.nlm.nih.gov/38889373</a></p></li><li><p>Jin, SJ, et al., &amp; Bae, KS (2012). The pharmacokinetics of letrozole: association with key body mass metrics. <i>International journal of clinical pharmacology and therapeutics</i> 50(8) 557–565. DOI:<a href=\"https://doi.org/10.5414/CP201709\">10.5414/CP201709</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22735458/\">https://pubmed.ncbi.nlm.nih.gov/22735458</a></p></li><li><p>Awada, A, et al., &amp; Piccart, M (2008). The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. <i>European journal of cancer (Oxford, England : 1990)</i> 44(1) 84–91. DOI:<a href=\"https://doi.org/10.1016/j.ejca.2007.10.003\">10.1016/j.ejca.2007.10.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18039566/\">https://pubmed.ncbi.nlm.nih.gov/18039566</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L02BG04;
